Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Post by wjon May 28, 2013 9:53pm
145 Views
Post# 21453739

10:30am-11:00am EDT, May 30, 2013

10:30am-11:00am EDT, May 30, 2013
Date Thursday, May 30, 2013

 

 

 

 

 

Presentation details as follows:  

  • Date and Time: 10:30am-11:00am EDT, May 30, 2013 
  • Venue: Grand Hyatt, New York, NY, Estate 6 Room 
  • Presenter: Neil Belenkie, Chief Executive Officer of Sirona Biochem

 

 

 

Grand Hyatt
109 E 42nd Street
New York, NY 10017

 

The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization. The Conference is expected to draw more than 1,000 attendees including senior personnel from almost 100 presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace. This year Marcum has partnered with KCSA Strategic Communications and Launchpad Investor Relations to host the conference.

This invitation-only event attracts institutional investors including top fund managers and qualified high net worth investors, who focus on small cap equities. One on One meetings are available for company management teams and qualified investors.

The conference will feature presentation tracks including:

  • Technology & Telecom
  • Social Media & Internet
  • Life Sciences
  • Retail & Consumer Products
  • Energy & Natural Resources
  • Industrials
  • Special Situations

This year we expect the Conference to draw more than 1,000 attendees including executive, finance and legal personnel from pre-IPO and smaller public companies, venture and lower middle-market private equity investors, directors, bankers and service providers to the microcap marketplace. Sponsoring the Marcum LLP MicroCap Conference will open doors to potential business that your firm may not find anywhere else.

Bullboard Posts